Abstract
Purpose
To investigate the influence of diabetic myocardial damage (suspected myocardial damage; SMD) diagnosed by201T1-SPECT and diabetic cardiac autonomic neuropathy (AN) on myocardial MIBG uptake in patients with non-insulin-dependent diabetes mellitus (NIDDM).
Subjects and Methods
Eighty-seven diabetic patients divided into four subgroups: 23 with SMD (+) AN (+); 19 with SMD (+) AN (−); 27 with SMD (−) AN (+); 18 with SMD (−) AN (−), and 10 controls were studied. Both planar and SPECT images were taken at 30 minutes (early) and 3 hours (delayed) after123I-MIBG injection. The heart to mediastinum uptake ratio (H/M) and washout ratio of123I-MIBG (WR) were obtained from both planar images. On SPECT images, the total uptake score (TUS) was obtained by the 5 point score method by dividing the myocardium into 20 segments on visual analysis. Similarly, the difference between the201Tl image and the123I-MIBG image in TUS was taken as the difference in the total uptake score (ΔTUS) representing cardiac sympathetic denervation without SMD.
Results
On both early and delayed planar images, the mean H/M value in the subgroups of diabetic patients was significantly lower in the SMD (+) AN (+) group than in the control group, but among those subgroups, there was statistically significant difference between the SMD (+) AN (+) and SMD (−) AN (−) groups only on the delayed images. Regarding the WR value, there was no statistically significant difference among subjects. On SPECT image analysis, the diabetic sub-group with AN or SMD had statistically significant lower values for TUS than those of the control group. Among diabetics, there was a statistically significant differences between SMD [+] AN [+] and SMD [−] AN [−] on both early and delayed images. Similarly, the SMD [+] AN [−] group also had significantly lower values than those of SMD [−] AN [−] on early images. Regarding ΔTUS, there was a statistically significant differences between AN [+] subgroups and controls. Similarly, the mean value for ΔTUS was much higher in AN [+] subgroups than in AN [−] subgroups with or without SMD in diabetes mellitus.
Conclusion
123I-MIBG myocardial uptake is affected by both SMD and cardiac autonomie neuropathy. Based on the finding that ΔTUS was much higher in AN [+] subgroups and there was no statistically significant difference between SMD [+] AN [+] and SMD [−] AN [+] subgroups, a decrease in myocardial123I-MIBG uptake might progress independently of SMD.
Similar content being viewed by others
References
Ewing DJ, Cambell IW, Clarke BF. The natural history of diabetic autonomic neuropathy.Q J Med 49: 95–108, 1980.
Nagamachi S, Jinnouchi S, Nakahara H, Flores LG, Ohnishi T, Hoshi H, et al.123I-MIBG myocardial scintigraphy in diabetic patients: Relationship to autonomic neuropathy.Nucl Med Commu 17: 621–632, 1996.
Mäntysaari M, Kuikka J, Mustonene J, Tahvanainen K, Vanninen E, Länsimies E, et al. Noninvasive detection of cardiac sympathetic nervous dysfunction in diabetic patients using [123I]metaiodobenzylguanidine.Diabetes 41: 1069–1075, 1992.
Kim SJ, Lee JD, Ryu YH, Jeon P, Shim YW, Yoo HS, et al. Evaluation of cardiac sympathetic neuronal integrity in diabetic patients using iodine-123 metaiodobenzyl guanidine.Eur J Nucl Med 23: 401–406, 1996.
Katono E, Owada K, Takeda H, Techigawara M, Watanabe N, Maruyama Y. Usefulness of myocardial imaging by123I-MIBG in assessment of diabetic neuropathy.Jpn J Nucl Med 30: 1235–1239, 1993.
Hattori N, Tamaki N, Hayashi T, Masuda I, Kudoh T, Tateno M, et al. Regional abnormality of iodine-123-MIBG in diabetic hearts.J Nucl Med 37: 1985–1990, 1996.
Dubois EA, Kam KL, Somsen GA, Boer GJ, Bruin K, Batink HD, et al. Cardiac iodine-123 metaiodobenzyl-guanidine uptake in animals with diabetes mellitus and/or hypertension.Eur J Nucl Med 23: 901–908, 1996.
Abe N, Kashiwagi A, Shigeta Y. Usefulness of cardiac125I-metaiodobenzylguanidine uptake for evaluation of cardiac sympathetic nerve abnormalities in diabetic rats.J Japan Diab Soc 35: 113–119, 1992.
Matsuo S, Takahashi S, Yoshida S, Tohru I, Nakamura Y, Mitsunami K, et al. Characteristics of regional sympathetic innervation in diabetic patients with silent myocardial ischemia assessed by123I-metaiodobenzyl guanidine imaging.Jpn J Nucl Med 33: 493–499, 1996.
Langer A, Freeman MR, Josse RG, Armstrong PW. Metaiodobenzylguanidine imaging in diabetes mellitus: Assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia.J Am Coll Cardiol 25: 610–618, 1995.
Matsuo S, Takahashi M, Nakamura Y, Kinoshita M. Evaluation of cardiac sympathetic innervation with iodine-123-metaiodobenzylguanidine imaging in silent myocardial ischemia.J Nucl Med 37: 712–717, 1996.
Hamby RI, Zoneraich S, Sherman L. Diabetic cardiomyopathy.JAMA 229: 1749–1754, 1974.
Rubier S, Dlugash J, Yuceoglu YZ, Kumal T, Branwood AM, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis.Am J Cardiol 30: 595–602, 1972.
Mizuno S, Genda A, Nakayama A, Igarashi Y, Takeda R. Myocardial involvement in diabetic patients evaluated by exercise thallium-201 scintigraphy and cardiac catheterization.J Cardiogr 15: 427–437, 1985.
Amano K, Sakamoto T, Oku J, Fujinami K, Sugimoto T. Diabetic cardiomyopathy in mild diabetics: evaluation by thallium-201 scintigraphy and exercise radionuclide ventriculography.J Cardiogr 16: 907–917, 1986.
Langer A, Freeman MR, Josse RG, Steiner G, Armstrong PW. Detection of silent myocardial ischemia in diabetes mellitus.Am J Cardiol 67: 1073–1078, 1991.
Bruce RA. Exercise testing of patients with coronary heart disease: principles and normal standards for evaluation.Ann Clin Res 3: 323–332, 1971.
Koistinen MJ. Prevalence of asymptomatic myocardial ischaemia in diabetic subjects.BMJ 301: 92–95, 1990.
Ueda N. Detection of diabetic autonomic neuropathy—Utilization of power spectral analysis of heart rate variability.J Japan Diab Soc 35: 17–23, 1992.
Hashimoto J, Hata M, Kondou M, Hirota A, Shima K. Normal reference values and prediction equation of autonomic nerve functions based on variations in the R-R interval in electrocardiographs.J Japan Diab Soc 30: 167–173, 1987.
Mori Y, Anzai K, Tashiro E, Takata T, Ohkubo K, Futata T, et al. Squatting test for the evaluation of diabetic cardiovascular autonomic neuropathy.J Japan Diab Soc 39: 857–865, 1996.
Maeno M, Ishida Y, Shimonagata T, Hayashida K, Toyama T, Hirose Y, et al. The significance of201T1/123I-MIBG (Metaiodobenzylguanidine) mismatched myocardial regions for predicting ventricular tachycardia in patients with idiopathic dilated cardiomyopathy.Jpn J Nucl Med 30: 1221–1229, 1993.
Wieland DM, Brown LE, Rogers WL, Worthington KC, Wu JL, Clinthrone NH, et al. Myocardial imaging with a radioiodinated norepinephrine storage analog.J Nucl Med 22:21–31, 1981.
Sisson JC, Wieland DM, Sherman P, Mangner TJ, Tobes MC, Jackes Jr S. Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function.J Nucl Med 28: 1620–1624, 1987.
Stanton MS, Tuli MM, Radtke NL, Heger JJ, Miles WM, Mock et al. Regional sympathetic denervation after myocardial infarction in humans detected noninvasively using I-123 metaiodobenzylguanidine.J Am Coll Cardiol 14: 1519–1526, 1989.
McGhie AL, Corbett JR, Akers MS, Kurkarni P, Sills MN, Kremers M, et al. Regional cardiac adrenergic function using I-123 metaiodobenzylguanidine tomographic imaging after acute myocardial infarction.Am J Cardiol 67: 236–242, 1991.
Ishida Y, Maeno M, Hirose Y, Takahashi N, Katabuchi T, Oka H, et al. Characteristic of regional sympathetic dys-function in acute ischemic myocardium assessed by123I-Metaiodobenzylguanidine imaging: Impairment of myocardial norepinephrine uptake of retention.Jpn J Nucl Med 32:631–642, 1995.
Kahn JK, Sisson JC, Vinik AI. QT interval prolongation and sudden cardiac death in diabetic autonomic neuropathy.J Clin Endocrinol Metab 64: 751–754, 1987.
Brismar T, Sima AA, Greene DA. Reversible and irreversible nodal dysfunction in diabetic neuropathy.Ann Neurol 21:504–507, 1987.
Ganguly PK, Beamish RE, Dhalla KS, Iinnes IR, Dhalla NS. Norepinephrine storage, distribution and release in diabetic cardiomyopathy.Am J Physiol 252: E734-E739, 1987.
Tsuchimochi S, Tamaki N, Tadamura E, Kawamoto M, Fujita T, Yonekura Y, et al. Age and gender differences in normal myocardial adrenergic neuronal function evaluated by Iodine-123-MIBG imaging.J Nucl Med 36: 969–974, 1995.
Bogaty P, Guimond J, Robitaille NM, Rousseau L, Simard S, Rouleau JR, et al. A reappraisal of exercise electrocardiographic indexes of the severity of ischemic heart disease: angiographie and scintigraphic correlates.J Am Coll Cardiol 29: 1497–1504, 1997.
Maddahi J, Rodrigues E, Kiat H, et al. Detection and evaluation of coronary artery disease by thallium-201 myocardial perfusion scintigraphy. InCardiac SPECT Imaging, Depuey EG, Berman DS, Garcia EV, eds., New York, Raven Press, pp. 103–120, 1994.
Holtz J, Mayer E, Bassenger E. Demonstration of a-adrenergic coronary control in different layers of canine myocardium by regional myocardial sympathetictomy.Pflugers Arch 187–194, 1977.
Stevens MJ, Dayanikli F, Raffel DM, Allman KC, Sandforf T, Feldman EL, et al. Scintigraphic assessment of regionalized defects in myocardial sympathetic innervation and blood flow regulation in diabetic patients with autonomic neuropathy.J Am Coll Cardiol 31: 1575–1584, 1998.
Nakajo M, Shimabukuro K, Yoshimura H, Yonekura R, Nakabeppu Y, Tanoue T, et al. Iodine-131 Metaiodobenzyl-guanidine. Intra- and Extra-vesicular accumulation in the rat heart.J Nucl Med 27: 84–89, 1986.
Merlet P, Valette H, Rande JL, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure.J Nucl Med 33: 471–477, 1992.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nagamachi, S., Jdmnouchi, S., Kurose, T. et al. 123I-MIBG myocardial scintigraphy in diabetic patients: Relationship with201Tl uptake and cardiac autonomic function. Ann Nucl Med 12, 323–331 (1998). https://doi.org/10.1007/BF03164921
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03164921